Califorrniaa v. Vidal: Supreme Court petition dismissed in 87 days
Eurica Califorrniaa petitioned the U.S. Supreme Court against USPTO Director Katherine K. Vidal over the patentability of US10245075B2, directed to nondestructive ectopic pregnancy management. The Court denied rehearing and the petition was dismissed, closing the case in under three months.
Supreme Court shuts the door on ectopic pregnancy patent challenge
On February 17, 2023, Eurica Califorrniaa filed Case No. 22-794 at the U.S. Supreme Court against Katherine K. Vidal in her capacity as Director of the USPTO. The dispute centres on US10245075B2 (application no. US14/214897), which covers a nondestructive means of ectopic pregnancy management. The case arose as a judicial review of a patentability determination — classified as an invalidity/cancellation action — placing the continued enforceability of the patent directly at issue.
The Court denied rehearing, and the recorded basis of termination is 'Petition Dismissed.' The case closed on May 15, 2023. The specific terms underlying the dismissal are not further disclosed in the available record. Califorrniaa appeared pro se, with Elizabeth B. Prelogar representing the respondent Vidal.
The 87-day duration from filing to closure is consistent with a petition dismissed at the certiorari or rehearing stage without full briefing on the merits. What drove the underlying patentability dispute — and what prior proceedings preceded this Supreme Court petition — is not detailed in the available record.
See Complete Case & Patent Analysis →Filing to Petition Dismissed in 87 days
Case closed in 87 days — from filing to dismissal at the Supreme Court level
US10245075B2 — nondestructive ectopic pregnancy management
Medical device developers, reproductive health technology companies, and clinical procedure innovators working in ectopic pregnancy management should assess exposure to US10245075B2. Although the patent's validity has been challenged — and a Supreme Court petition was dismissed without merits ruling — the patent remains in the public record and its enforceability is governed by the USPTO proceedings below. Any product or method touching nondestructive ectopic pregnancy management warrants a formal FTO review.
Official order — verbatim text
The recorded verdict — 'Rehearing DENIED' — indicates the Supreme Court declined to reconsider a prior denial of certiorari or other dispositive order. Combined with the recorded basis of termination ('Petition Dismissed'), this confirms the case ended without any substantive merits ruling on the patentability of US10245075B2; the underlying USPTO determination remains the operative decision.
Petition dismissed: what the Supreme Court's denial means for both parties
What 'Petition Dismissed' means at the Supreme Court
A dismissed petition at the Supreme Court level — following denial of rehearing — means the Court declined to exercise jurisdiction or reconsider the matter. No merits ruling was issued on the underlying patentability question. The decision below, as resolved by the USPTO or the relevant lower tribunal, stands as the operative determination.
No merits adjudicationPetitioner's final avenue closed without relief
For Califorrniaa, the dismissal following a denied rehearing represents the exhaustion of this particular appellate path. The Supreme Court's refusal to hear the matter means the patentability challenge — as resolved in prior proceedings — was not disturbed in the petitioner's favour at this level. What remedies, if any, remain available is not addressed in the available record.
Petition path exhaustedUSPTO director's position upheld by default
Katherine K. Vidal, as USPTO Director, effectively prevails in the sense that no Supreme Court intervention altered the USPTO's patentability determination. The dismissal without merits review leaves the agency's prior decision intact. The Solicitor General's office, representing Vidal, did not need to defend the substance on the merits at this stage.
Agency determination standsPatent status remains governed by the underlying USPTO ruling
With the Supreme Court petition dismissed, the commercial and legal status of US10245075B2 continues to be shaped by whatever determination was reached in the proceedings below. Parties in the nondestructive ectopic pregnancy management technology space should monitor the underlying USPTO record directly. The Supreme Court dismissal adds no new substantive guidance on the patent's validity or scope.
Monitor USPTO recordFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Eurica Califorrniaa | Individual | /Search in Eureka ↗ |
| Defendant | Katherine K. Vidal | Individual | /Search in Eureka ↗ |
| Plaintiff counsel | Eurica Califorrniaa | Attorney | Counsel for Eurica CaliforrniaaSearch in Eureka ↗ |
| Defendant counsel | Elizabeth B. Prelogar | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | U.S. Supreme CourtSearch in Eureka ↗ |
R&D signals in nondestructive ectopic pregnancy management IP
Forward-looking patent and innovation intelligence for the reproductive health technology space, drawn from the IP activity surrounding US10245075B2 and related medical method filings.
Califorrniaa's patent activity in reproductive health methods
Eurica Califorrniaa's assertion of US10245075B2 through USPTO proceedings to the Supreme Court suggests an active enforcement posture for this portfolio. R&D teams should map any additional filings by this inventor in the ectopic pregnancy or related obstetric intervention space to understand the full scope of the IP position being defended.
Inventor portfolio watchFiling trends in nondestructive ectopic pregnancy intervention
The ectopic pregnancy management space sits at the intersection of minimally invasive surgical techniques and pharmacological intervention. Patent filing trends in this domain — particularly around nondestructive or organ-sparing approaches — are worth monitoring as clinical interest in fertility-preserving methods grows. Identifying the most active assignees and filing jurisdictions can reveal where competitive IP risk is concentrating.
Filing trend analysisUSPTO and agency IP posture in contested medical methods
The USPTO's defence of its patentability determination — through the Solicitor General to the Supreme Court — reflects the agency's standard posture in validity disputes. R&D teams should note that USPTO patentability rulings on medical method patents are well-entrenched absent Congressional or Federal Circuit intervention; designing around an invalidated claim may be a more commercially efficient path than continued challenge.
Agency IP postureAdjacent innovation space in ectopic pregnancy diagnostics and treatment
While US10245075B2 covers a nondestructive management approach, adjacent white space exists in early ectopic pregnancy detection, biomarker-based diagnosis, and image-guided intervention tools. These areas may carry lower prior-art density and § 101 eligibility risk. Teams looking to build IP in reproductive health should evaluate whether these adjacent domains offer stronger patentability prospects.
Adjacent white spaceSimilar patent patentability disputes at the U.S. Supreme Court
Explore comparable medical method and patentability petitions dismissed or denied at the U.S. Supreme Court, including invalidity challenges to health-related patents.
What this case signals for the medical device patent IP landscape
A Supreme Court petition dismissed in under 90 days, with no merits ruling, leaves the underlying USPTO patentability decision as the controlling authority.
USPTO patentability rulings are highly resilient at the Supreme Court level
This case is consistent with the well-established pattern that the Supreme Court grants certiorari in a very small fraction of patent cases. A petition dismissed following rehearing denial signals that the underlying USPTO determination — whatever it was — survived the highest available appellate challenge without judicial intervention.
Pro se Supreme Court petitions in patent disputes face steep procedural barriers
Califorrniaa appeared without counsel. Pro se litigants at the Supreme Court face significant procedural and substantive challenges. IP professionals should note that the absence of specialist patent counsel at this stage typically correlates with early procedural dismissal rather than merits engagement.
Califorrniaa v Katherine — key questions answered
The U.S. Supreme Court denied rehearing and the petition was dismissed. The recorded basis of termination is 'Petition Dismissed.' No merits ruling was issued on the patentability of US10245075B2. The case closed on May 15, 2023, 87 days after filing.
The patent at issue is US10245075B2, filed under application number US14/214897. It covers a nondestructive means of ectopic pregnancy management. The case was classified as a patentability dispute — specifically an invalidity/cancellation action — before the USPTO, with Califorrniaa seeking Supreme Court review of the underlying determination.
The petitioner was Eurica Califorrniaa, who appeared pro se (without counsel). The respondent was Katherine K. Vidal in her capacity as Director of the USPTO, represented by Elizabeth B. Prelogar, the U.S. Solicitor General.
The dismissal was issued without a merits ruling on patentability. This means the Supreme Court did not adjudicate the validity or invalidity of US10245075B2. The patent's status is governed by the underlying USPTO proceedings. Parties assessing FTO or validity risk should consult the USPTO record directly.
A 'Petition Dismissed' outcome at the Supreme Court — particularly following a denied rehearing — means the Court declined to exercise further jurisdiction. No substantive ruling on the underlying legal question is issued. The decision reached in the lower proceedings (here, the USPTO patentability determination) stands as the operative authority.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.